Shares of ANI Pharmaceuticals Inc. (NASDAQ:ANIP) were down 1.1% during mid-day trading on Wednesday . The company traded as low as $63.02 and last traded at $64.10, with a volume of 83,345 shares trading hands. The stock had previously closed at $64.84.

A number of analysts have issued reports on ANIP shares. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $67.00 price target on the stock in a report on Wednesday, July 20th. Raymond James Financial Inc. started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, June 22nd. They issued a “strong-buy” rating and a $68.00 price target on the stock. Citigroup Inc. downgraded shares of ANI Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $49.00 price target on the stock. in a report on Friday, July 8th. They noted that the move was a valuation call. Standpoint Research downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 24th. Finally, TheStreet upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 26th. One analyst has rated the stock with a hold rating, five have issued a buy rating and three have given a strong buy rating to the company’s stock. ANI Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $64.00.

The stock has a market capitalization of $749.79 million, a PE ratio of 76.52 and a beta of 2.84. The company has a 50-day moving average price of $64.75 and a 200-day moving average price of $52.16.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/ani-pharmaceuticals-inc-anip-stock-price-down-1-1.html

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.34. ANI Pharmaceuticals had a net margin of 11.02% and a return on equity of 20.12%. The firm had revenue of $31.30 million for the quarter, compared to the consensus estimate of $27.63 million. During the same period in the prior year, the firm posted $0.55 earnings per share. The firm’s quarterly revenue was up 60.5% compared to the same quarter last year. Equities analysts predict that ANI Pharmaceuticals Inc. will post $4.12 earnings per share for the current year.

In other ANI Pharmaceuticals news, VP Robert W. Schrepfer sold 12,500 shares of the stock in a transaction on Monday, August 8th. The shares were sold at an average price of $67.06, for a total transaction of $838,250.00. Following the transaction, the vice president now directly owns 17,362 shares of the company’s stock, valued at $1,164,295.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Arthur Przybyl sold 37,455 shares of the stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $66.97, for a total transaction of $2,508,361.35. Following the transaction, the insider now directly owns 200,788 shares in the company, valued at $13,446,772.36. The disclosure for this sale can be found here. Corporate insiders own 31.60% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA increased its position in ANI Pharmaceuticals by 94.9% in the second quarter. BNP Paribas Arbitrage SA now owns 2,364 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 1,151 shares during the last quarter. Bank of Montreal Can bought a new position in ANI Pharmaceuticals during the second quarter valued at about $177,000. Thrivent Financial for Lutherans bought a new position in ANI Pharmaceuticals during the second quarter valued at about $204,000. Arizona State Retirement System bought a new position in ANI Pharmaceuticals during the second quarter valued at about $219,000. Finally, BlackRock Advisors LLC increased its position in ANI Pharmaceuticals by 6.1% in the second quarter. BlackRock Advisors LLC now owns 3,975 shares of the specialty pharmaceutical company’s stock valued at $222,000 after buying an additional 230 shares during the last quarter. 48.74% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

5 Day Chart for NASDAQ:ANIP

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.